Monday, April 25, 2011 3:27:06 PM
March 31, 2011 — 11:27am ET | By John Carroll
* Merck scoots past Vertex in blockbuster race for hep C drug approval
* Merck's boceprevir scores high in PhIII hep C trial
* Schering-Plough posts positive hep C data
* Vertex boosted by new round of promising telaprevir data
* Vertex trims a telaprevir study from its slate of hep C work
There are no sure things in drug development, but physicians across the country are clearly waiting in expectation of the near-term approval of two new hepatitis C drugs--telaprevir and boceprevir--which promise to revolutionize treatment of the disease. And that bodes well for Vertex and Merck, which developed two of the hottest drug prospects now up for an approval.
While most developers facing an FDA decision go through a nail-biting episode of extreme uncertainty, Vertex and Merck are being treated to a pre-approval round of celebratory reports in a host of media outlets.
"This is opening up a new door" for treatment of hepatitis C, Dr. Raymond Koff of the University of Connecticut School of Medicine tells the Los Angeles Times. Dr. Stuart Gordon, a hepatitis C researcher at Detroit's Henry Ford Hospital, tells the Detroit Free Press that the two drugs represent "a major advance in the cure of a very common disease."
The rave reviews are likely to help pave a short path to blockbuster sales for the two companies. With patients and physicians anxiously awaiting approval, the initial demand for both therapies will be strong.
- read the story from the Los Angeles Times
- here's the report from the Detroit Free Press
Related Articles:
Vertex boosted by new round of promising telaprevir data
Vertex wins an expedited review of telaprevir app
Merck scoots past Vertex in blockbuster race for hep C drug approval
Merck's boceprevir scores high in PhIII hep C trial
Recent VRTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 08:10:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/02/2024 08:03:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:17:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:05:43 PM
- Vertex Reports Second Quarter 2024 Financial Results • Business Wire • 08/01/2024 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 07:34:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/30/2024 07:25:57 PM
- Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain • Business Wire • 07/30/2024 05:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2024 08:06:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:05:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/24/2024 04:27:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/22/2024 05:16:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:13:27 PM
- Santé Canada autorise la commercialisation de TRIKAFTA(MD) (éléxacaftor/tézacaftor/ivacaftor et ivacaftor) chez les personnes atteintes de fibrose kystique âgées de 2 ans et plus présentant certaines mutations rares • PR Newswire (Canada) • 07/15/2024 01:00:00 PM
- Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations • PR Newswire (Canada) • 07/15/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:07:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/10/2024 02:27:12 PM
- Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis • Business Wire • 07/02/2024 12:33:00 PM
- Vertex to Announce Second Quarter 2024 Financial Results on August 1 • Business Wire • 07/01/2024 08:05:00 PM
- Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions • Business Wire • 06/21/2024 07:45:00 PM
- Vertex Announces Extended Long-Term Reimbursement Agreement with NHS England for Access to Cystic Fibrosis Medicines KAFTRIO®, SYMKEVI® and ORKAMBI® • Business Wire • 06/20/2024 11:15:00 AM
- Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress • Business Wire • 06/14/2024 07:03:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:11:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:09:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/12/2024 01:56:43 PM
FEATURED North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • Aug 5, 2024 9:00 AM
Fifty 1 Labs, Inc. and All-In-Extracts Announce Joint Venture to Develop and Release New Testosterone Boosting Supplement • BLEG • Aug 5, 2024 8:30 AM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM